Very Early FDG-PET/CT-response Adapted Therapy for Advanced Hodgkin Lymphoma (H11)
Status:
Withdrawn
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The main objective of the trial is to show that doxorubicin, bleomycin, vinblastine, and
dacarbazine (ABVD)-based response-adapted therapy for advanced-stage Hodgkin lymphoma, with
treatment intensification (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine,
procarbazine, and prednisone (BEACOPPesc) in case of a positive fluorodeoxyglucose (FDG)
positron emission tomography (PET) computed tomography (CT) after one cycle of ABVD, has
non-inferior efficacy compared with the intensive BEACOPPesc regimen. A second objective is
to assess the prognostic value of FDG-PET/CT after one cycle of BEACOPPesc.
Phase:
Phase 3
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC